查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1794527

全球核能药局市场

Nuclear Pharmacy
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 275 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2030年，全球核能药局市场规模将达86亿美元

全球核能药局市场规模预计在2024年为61亿美元，到2030年将达到86亿美元，2024年至2030年的复合年增长率为5.8%。设施类型是本报告分析的细分市场之一，预计其复合年增长率为4.5%，到分析期结束时规模将达到48亿美元。商业类型细分市场在分析期间内的复合年增长率预计为7.7%。

美国市场规模估计为 17 亿美元，中国市场预期复合年增长率为 9.0%

美国核能药市场规模预计2024年达到17亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到17亿美元，在2024-2030年的分析期间内，复合年增长率为9.0%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为3.0%和5.7%。在欧洲，预计德国市场的复合年增长率为3.8%。

全球核能药局市场－主要趋势与驱动因素摘要

为什么核能药学在现代医疗保健中越来越受到关注？

核能医学药局已成为诊断和治疗医学的重要组成部分，因为它们在核子医学摄影影像和标靶治疗所用放射性药物的製备中发挥关键作用。随着肿瘤科、心臟科和神经科对精准诊断的需求日益增长，核医药局已成为向影像中心和医院提供时间敏感、病患特异性放射性药物的关键。这些化合物能够在分子层面上可视化生物过程，从而能够更早发现疾病并更精确地监测治疗反应。

除了诊断影像外，核能药房也在拓展其在治疗诊断学的作用，即将治疗和诊断功能整合到单一放射性药物中。这种整合支持更个人化的患者照护方法，其中特定同位素可用于识别和治疗肿瘤。随着医疗保健向微创和标靶治疗转变，核能药局预计将在临床工作流程中发挥越来越重要的作用。

放射性药物和同位素生产的进步如何推动成长？

新型放射性药物的开发正在拓展核能药学的应用范围，使其超越Technetium-99m和氟-18等传统示踪剂。新的药物正在被设计用于更特异性的疾病靶点，包括用镏-177和镓-68等同位素标记的胜肽和抗体。这些化合物正用于治疗前列腺癌、神经内分泌肿瘤和其他疑难杂症，为专业化核能药学运作创造了机会。

同位素生产也正在经历变革时期。基于迴旋加速器和发生器的生产技术正在提高短寿命同位素的可靠性和本地可用性，减少对老化核子反应炉的依赖。自动化合成模组和品管系统正在改进放射性药物的製备，标准化剂量，并降低药剂师的暴露风险。这些创新支持以更快、更安全、更具可扩展性的方式向医疗保健专业人员提供放射性药物。

市场扩张的结构和监管驱动因素是什么？

核能药房在处理放射性物质方面受到严格的监管。遵守国家和国际标准需要专门的基础设施、人员培训和许可，这限制了能够进行大规模运作的设施数量。然而，集中式、连网的放射性药物药房的成长正在帮助医疗保健系统改善物流，减少废弃物，并确保准时交付短半衰期放射性药物。

门诊诊断中心和综合护理网络的兴起进一步影响了核能药房的扩张。许多医疗系统正在投资内部或附属的放射性药物生产能力​​，以减少对外部供应商的依赖。公共和私人对肿瘤学的资助，加上监管机构对新型放射性药物的快速反应，正在加强供应链并加速市场发展。製药公司、同位素製造商和医疗保健提供者之间的伙伴关係也在不断涌现，以满足日益增长的临床需求。

核能药局市场的成长受到多种因素的推动。

核子医学影像和治疗诊断学在肿瘤学、循环系统和神经病学中的应用日益广泛，这推动了对及时、高品质放射性药物的需求。新型同位素和靶向放射性示踪剂的开发正在扩大临床应用范围。自动化合成和同位素生产技术的进步正在提高操作效率和安全性。集中式放射性药物製造模式的扩展使得人们能够更广泛地获得时间关键型诊断剂。对新型放射治疗的监管支持和对个人化医疗的不断增长的投资正在加强核能药房与标准治疗通讯协定的整合。这些综合因素正在为全球核能药局市场创造强劲的成长轨迹。

部分

类型（设施类型、商业类型）；用途（诊断、治疗）

受访公司范例

  • Advanced Accelerator Applications（AAA）
  • Bayer AG（Radiopharma division）
  • Bracco Imaging SpA
  • Cardinal Health, Inc.（Nuclear Pharmacy）
  • Curium Pharma
  • Eczacibasi-Monrol Nuclear Products
  • Eckert & Ziegler（Radiopharma division）
  • GE HealthCare（Nuclear Pharmacy Services）
  • IBA Molecular Imaging
  • Jubilant Radiopharma（Jubilant DraxImage）
  • Lantheus Medical Imaging, Inc.
  • Mallinckrodt plc.（Nuclear Imaging）
  • NTP Radioisotopes SOC Ltd.
  • Nihon Medi-Physics Co., Ltd.
  • Nordion Inc.（Sotera Health）
  • Novartis（Advanced Accelerator Applications）
  • PharmaLogic Holdings Corp.
  • Siemens Healthineers
  • Shine Technologies（SHINE Medical）
  • Telix Pharmaceuticals Limited

人工智慧集成

利用检验的专家内容和 AI 工具转变您的市场和竞争情报。

Global 特定产业产业SLM 的典型规范，而是建立了一个从世界各地专家收集的内容库，包括影片录影、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地和进出口（成品和原始设备製造商）情况预测其竞争地位的变化。这种复杂而多面的市场动态预计将以多种方式影响竞争对手，包括销货成本(COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 竞赛

简介目录
Product Code: MCP37521

Global Nuclear Pharmacy Market to Reach US$8.6 Billion by 2030

The global market for Nuclear Pharmacy estimated at US$6.1 Billion in the year 2024, is expected to reach US$8.6 Billion by 2030, growing at a CAGR of 5.8% over the analysis period 2024-2030. Institutional Type, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$4.8 Billion by the end of the analysis period. Growth in the Commercial Type segment is estimated at 7.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.7 Billion While China is Forecast to Grow at 9.0% CAGR

The Nuclear Pharmacy market in the U.S. is estimated at US$1.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 9.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 5.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Global Nuclear Pharmacy Market - Key Trends & Drivers Summarized

Why Is Nuclear Pharmacy Gaining Prominence in Modern Healthcare?

Nuclear pharmacy is emerging as a critical component of diagnostic and therapeutic medicine due to its role in preparing radiopharmaceuticals used in nuclear imaging and targeted treatments. As demand rises for precision diagnostics in oncology, cardiology, and neurology, nuclear pharmacies are becoming essential in supplying time-sensitive, patient-specific radiotracers to imaging centers and hospitals. These compounds help visualize biological processes at the molecular level, enabling early detection of disease and more accurate monitoring of treatment response.

In addition to diagnostic imaging, nuclear pharmacy plays a growing role in theranostics-where therapeutic and diagnostic capabilities are combined in a single radiopharmaceutical. This integration supports a more personalized approach to patient care, where specific isotopes can be used to both identify and treat tumors. As healthcare shifts toward minimally invasive and targeted interventions, nuclear pharmacy is expected to play an increasingly central role in clinical workflows.

How Are Advancements in Radiopharmaceuticals and Isotope Production Driving Growth?

The development of new radiopharmaceuticals is expanding the scope of nuclear pharmacy beyond conventional tracers such as technetium-99m and fluorine-18. Novel agents are being designed for more specific disease targeting, including peptides and antibodies labeled with isotopes like lutetium-177 and gallium-68. These compounds are being used in the management of prostate cancer, neuroendocrine tumors, and other hard-to-treat conditions, creating opportunities for specialized nuclear pharmacy operations.

Isotope production is also undergoing transformation. Cyclotron and generator-based production techniques are improving reliability and local availability of short-lived isotopes, reducing dependency on aging nuclear reactors. Automated synthesis modules and quality control systems are improving radiopharmaceutical preparation, standardizing dosage, and reducing exposure risks to pharmacy personnel. These innovations are supporting faster, safer, and more scalable delivery of radiotracers to healthcare providers.

What Structural and Regulatory Factors Influence Market Expansion?

Nuclear pharmacy operates under strict regulatory controls given the handling of radioactive materials. Compliance with national and international standards requires specialized infrastructure, staff training, and licensing, which limits the number of facilities that can operate at scale. However, growth in centralized and networked radiopharmacies is helping healthcare systems improve logistics, reduce waste, and ensure on-time delivery of radiopharmaceuticals with short half-lives.

The rise of outpatient diagnostic centers and integrated care networks is further influencing nuclear pharmacy expansion. Many health systems are investing in in-house or partnered radiopharmacy capabilities to reduce reliance on external suppliers. Public and private funding in cancer care, coupled with regulatory fast-tracking of novel radiotherapeutics, is strengthening supply chains and accelerating market development. Partnerships between pharmaceutical companies, isotope producers, and healthcare providers are also emerging to meet rising clinical demand.

Growth in the nuclear pharmacy market is driven by several factors.

Increased use of nuclear imaging and theranostics in oncology, cardiology, and neurology is boosting demand for timely, high-quality radiopharmaceuticals. Development of novel isotopes and targeted radiotracers is expanding the range of clinical applications. Advances in automated synthesis and isotope production technologies are improving operational efficiency and safety. Expansion of centralized radiopharmacy models is enabling wider access to time-sensitive diagnostic agents. Regulatory support for new radiotherapeutics and growing investment in personalized medicine are reinforcing the integration of nuclear pharmacy into standard care protocols. These factors are collectively shaping a strong growth trajectory for the nuclear pharmacy market globally.

SCOPE OF STUDY:

The report analyzes the Nuclear Pharmacy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Institutional Type, Commercial Type); Purpose (Diagnostic, Therapeutic)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Advanced Accelerator Applications (AAA)
  • Bayer AG (Radiopharma division)
  • Bracco Imaging S.p.A.
  • Cardinal Health, Inc. (Nuclear Pharmacy)
  • Curium Pharma
  • Eczacibasi-Monrol Nuclear Products
  • Eckert & Ziegler (Radiopharma division)
  • GE HealthCare (Nuclear Pharmacy Services)
  • IBA Molecular Imaging
  • Jubilant Radiopharma (Jubilant DraxImage)
  • Lantheus Medical Imaging, Inc.
  • Mallinckrodt plc. (Nuclear Imaging)
  • NTP Radioisotopes SOC Ltd.
  • Nihon Medi-Physics Co., Ltd.
  • Nordion Inc. (Sotera Health)
  • Novartis (Advanced Accelerator Applications)
  • PharmaLogic Holdings Corp.
  • Siemens Healthineers
  • Shine Technologies (SHINE Medical)
  • Telix Pharmaceuticals Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Nuclear Pharmacy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Targeted Diagnostic Imaging Drives Growth in Nuclear Pharmacy Services
    • Expansion of PET and SPECT Imaging in Oncology, Cardiology, and Neurology Boosts Radiopharmaceutical Usage
    • Increased Availability of Short-Lived Isotopes Spurs Growth in Centralized and In-Hospital Nuclear Pharmacies
    • Advancements in Cyclotron and Generator Technologies Enhance On-Demand Radiotracer Production
    • Regulatory Approvals for New Radiolabeled Drugs Strengthen Market for Precision Diagnostic Tools
    • Shift Toward Personalized Medicine Throws the Spotlight on Radiotheranostics and Companion Diagnostics
    • Growing Use of Radiopharmaceuticals in Therapeutic Applications Expands Scope of Nuclear Pharmacy Operations
    • Integration of Automation and Robotics in Radiopharmacies Improves Accuracy, Safety, and Throughput
    • Expansion of Academic and Clinical Research Programs Fuels Demand for Custom Radiopharmaceutical Compounding
    • Rising Incidence of Chronic and Age-Related Diseases Accelerates Investment in Nuclear Imaging Infrastructure
    • Improvements in Cold-Chain Logistics and Dose Scheduling Support Wider Distribution of Time-Sensitive Isotopes
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Nuclear Pharmacy Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Nuclear Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Nuclear Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Nuclear Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Institutional Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Institutional Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Institutional Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Commercial Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Commercial Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Commercial Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Diagnostic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Therapeutic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Therapeutic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Therapeutic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • JAPAN
    • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • CHINA
    • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: China 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • EUROPE
    • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Nuclear Pharmacy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Nuclear Pharmacy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for Nuclear Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • FRANCE
    • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: France Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: France 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • GERMANY
    • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Germany 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Italy 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: UK 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 74: Spain Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Spain Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Spain 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 80: Russia Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Russia Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Russia 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Nuclear Pharmacy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Nuclear Pharmacy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Nuclear Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 101: Australia Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Australia Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Australia 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • INDIA
    • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 107: India Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: India Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: India 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 110: India Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 113: South Korea Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: South Korea Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: South Korea 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 119: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Asia-Pacific Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Rest of Asia-Pacific 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 125: Latin America Recent Past, Current & Future Analysis for Nuclear Pharmacy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 126: Latin America Historic Review for Nuclear Pharmacy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Latin America 16-Year Perspective for Nuclear Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 134: Argentina Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Argentina Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Argentina 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 140: Brazil Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Brazil Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Brazil 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 146: Mexico Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Mexico Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Mexico 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 152: Rest of Latin America Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Latin America Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Rest of Latin America 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 158: Middle East Recent Past, Current & Future Analysis for Nuclear Pharmacy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 159: Middle East Historic Review for Nuclear Pharmacy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Middle East 16-Year Perspective for Nuclear Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 167: Iran Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Iran Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Iran 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 173: Israel Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Israel Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Israel 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 179: Saudi Arabia Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Saudi Arabia Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Saudi Arabia 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 185: UAE Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: UAE Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: UAE 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 191: Rest of Middle East Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Middle East Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Middle East 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • AFRICA
    • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 197: Africa Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Africa Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Africa 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030

IV. COMPETITION